您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > PPA-904
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
PPA-904
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
PPA-904图片
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
20mg电议

产品介绍
PPA-904是一种特异性的吩噻嗪光敏剂,用于光动力疗法。

Animal experiment:

Mice: 106 metacyclic parasites in 20 mL of PBS are inoculated intradermally into the ears of 6- to 8-week-old BALB/c female mice. A PPA904 cream is applied topically onto the lesion under dark conditions. The areas in the right ear are then irradiated with LC-122A, non-coherent light source equipped with a broadband optical filter, which is inserted into the light delivery system. The filter peaks at 665 nm and has a half-band width of 30 nm. A fluence of 50 J/cm2 (50 mW/cm2) is delivered to the lesion on the right ear, while the left ear (and left ears of the other mice in this group) serves as the drug only group. The ears from mice with no procedure serve as the infected nontreated group. Mice are sacrificed 5 days after photodynamic therapy. Parasite loads in the ears are determined[1].

产品描述

PPA-904 is a specific phenothiazine photosensitizer used in photodynamic therapy.

Topical PPA904 photodynamic therapy is a promising treatment for cutaneous leishmaniasis. The best curative PPA904-photodynamic therapy regimen is achieved under the conditions of a longer duration of topical application time (90 minutes) and several (three) consecutive treatments with 4-day intervals between treatments[1]. PPA904-PDT can provide an immunomodulating, dose-dependent efflux on IL-12p70 production. This mechanism could be responsible for promoting a more rapid healing in PPA904-PDT treated mice[2]. Treatment of PPA904 is well tolerated with no reports of pain or other safety issues. PPA904 treated subjects show a reduction in bacterial load immediately post-treatment. After 3 months, 50% (four of eight) of subjects with actively treated chronic leg ulcer show complete healing, compared with 12% (one of eight) of subjects on placebo[3].

[1]. Akilov OE,et al. Optimization of topical photodynamic therapy with 3,7-bis(di-n-butylamino)phenothiazin-5-ium bromide for cutaneous leishmaniasis. Lasers Surg Med. 2009 Jul;41(5):358-65. [2]. Akilov OE, et al. Photodynamic therapy for cutaneous leishmaniasis: the effectiveness of topical phenothiaziniums in parasite eradication and Th1 immune response stimulation. Photochem Photobiol Sci. 2007 Oct;6(10):1067-75. [3]. Morley S, et al. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol. 2013 Mar;168(3):617-24.